Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 9,396

Document Document Title
WO/2008/024021A1
The invention relates to the pharmaceutical industry and to medicine, in particular to a novel highly active antioxidant which is used for preventing and treating diseases caused by oxidative stress and scarcity of oxygen in an organism ...  
WO/2008/022365A2
The use of galanthamine of the formula (I) and derivatives or analogues of galanthamine for controlling the effect of toxic organic phosphorus compounds such as parathion, paraxon, sarin, soman or tabun is described, wherein a compositio...  
WO/2008/018133A1
The invention relates to a moisturizing agent, a cell-activating agent, a skin-whitening agent, an agent for suppressing triglyceride accumulation and an antioxidant containing as an active ingredient, one or more plants selected from pl...  
WO/2008/018142A1
It is intended to provide a composition which exerts an excellent antioxidant effect in vivo. Namely, an antioxidant composition characterized by containing a component originating in the bark of a tree belonging to the genus Acacia.  
WO/2008/015867A1
Disclosed is a method for activating dissolved hydrogen molecules in water and stabilizing the hydrogen molecule concentration. Specifically disclosed is a method for activating and stabilizing dissolved hydrogen molecules in water, whic...  
WO/2008/016378A3
The present invention relates to methods useful for treating and/ or preventing radiation- and/ or chemical-induced toxicity in non-malignant tissue using a protease activated receptor- 1 (PAR-I) inhibitor. In particular, use of a protea...  
WO/2008/016378A2
The present invention relates to methods useful for treating and/ or preventing radiation- and/ or chemical-induced toxicity in non-malignant tissue using a protease activated receptor- 1 (PAR-I) inhibitor. In particular, use of a protea...  
WO/2008/016123A1
Disclosed is a GSK-3β inhibitor comprising an oxadiazole compound or a salt or prodrug thereof which is useful as a prophylactic/therapeutic agent for a GSK-3β-related condition or disease. The GSK-3β inhibitor comprises a compound re...  
WO/2008/013219A1
Disclosed is a composition which enables the increased in-vivo absorption of cryptoxanthin derived from a natural product, particularly cryptoxanthin derived from Unshu-orange which is known to contain cryptoxanthin in a large quantity. ...  
WO/2008/010403A1
The invention is directed to a method for preventing coloration of catechins by adding to catechins, a water-soluble polymer capable of forming a water-insoluble complex with catechins; and hydrogel particles containing a water-insoluble...  
WO/2007/147590A3
The present invention concerns a solution and methods to reduce, treat and/or prevent oxidative stress and cell activation. According to the invention the solution gives rise to the following concentrations of constituents within a blood...  
WO/2007/147590A2
The present invention concerns a solution and methods to reduce, treat and/or prevent oxidative stress and cell activation. According to the invention the solution gives rise to the following concentrations of constituents within a blood...  
WO/2007/145682A1
A composition for oral radionuclide chelation therapy comprises a DTPA chelate selected from Zn-DTPA and Ca-DTPA and a permeation enhancer that preferentially increases jejunal uptake of the DTPA chelate. The composition has a DTPA chela...  
WO/2007/143858A1
Diphtheria and Pseudomonas infections are very common worldwide. The toxins involved in the pathogenesis of those diseases act by inactivating the elongation factor-2 (EF-2), therefore blocking protein synthesis and leading to cell death...  
WO/2007/143851A1
The present application concerns plant extracts which have been fermented with kephir grains, methods of production of these extracts, a powder comprising these extracts and compositions comprising these extracts. Since these extracts ha...  
WO/2007/140551A2
The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.  
WO/2007/143066A2
Provided is a method for determining whether an individual is likely to be susceptible to radiation pneumonitis from radiation therapy and for developing a treatment based on the determination of susceptibility. The method involves measu...  
WO/2007/140551A3
The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.  
WO/2007/139153A1
It is intended to provide a function-improving agent for cerebral dysfunction caused by an environmental chemical. According to the invention, the function-improving agent for cerebral dysfunction caused by an environmental chemical cont...  
WO/2007/135241A3
This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/...  
WO/2007/135241A2
This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/...  
WO/2007/135242A1
This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/...  
WO/2007/133076A2
The current invention provides new methods and means for the prevention and treatment of ageing-related symptoms and diseases. The invention discloses mannitol and/or proline containing compositions that are particularly useful for the t...  
WO/2007/133076A3
The current invention provides new methods and means for the prevention and treatment of ageing-related symptoms and diseases. The invention discloses mannitol and/or proline containing compositions that are particularly useful for the t...  
WO/2007/132418A1
The present invention concerns to the use of salicylate in the treatment of mammal intoxications caused by the herbicide paraquat (PQ). It was achieved, for the first time, 100% of survival 30 days after the administration to Wistar rats...  
WO2006089537A8
The invention relates to a method for production of an oral, rectal or vaginal preparation comprising a solid silicone oil emulsion, characterised in that said preparation comprises 0.01 - 85 wt. % dimethicone and 0.01 - 45 wt. % dimethy...  
WO/2007/125946A1
Disclosed are: an antioxidant agent which comprises, as an active ingredient, a peptide having an antioxidative effect and an adiponectin production-promoting effect and comprising the amino acid sequence represented by the formula: His-...  
WO/2007/124610A1
The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said an...  
WO/2007/125832A1
A new action of Helipyrone A is now found. As a useful application of Helipyrone A, the following agent is disclosed: a singlet oxygen scavenger, an anti-skin-aging agent, an anti-wrinkle agent, an anti-sagging agent, an agent for improv...  
WO/2007/124734A2
A compound of the formula A-R-X or pharmaceutically acceptable salts thereof can be used to manufacture a pharmaceutical preparation which serves to prevent or treat cancers, pathological sequelae of alcohol abuse, viral hepatitis, steat...  
WO/2007/124734A3
A compound of the formula A-R-X or pharmaceutically acceptable salts thereof can be used to manufacture a pharmaceutical preparation which serves to prevent or treat cancers, pathological sequelae of alcohol abuse, viral hepatitis, steat...  
WO/2007/123284A1
The present invention relates to an alpha lipoic acid capsule composition stabilized in aqueous phase, which can effectively prevent alpha lipoic acid from decomposing due to external environmental conditions, such as water, temperature,...  
WO/2007/119367A1
Tetrahydrobiopterin (BH4) to be used as a pharmaceutical has an excellent efficacy, therefore, expansion of use or application thereof is considered. However, because BH4 is expensive and unstable to oxidation, its application to other t...  
WO/2007/118276A1
The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or ot...  
WO/2007/118967A1
This invention relates to the use of cholest-4-in-3-one derivatives to obtain a cytoprotective medicine, excluding a neuroprotective medicine.  
WO/2007/116916A1
[PROBLEMS] To provide a liquid drug preparation for oral preparation by which the labor at drug-taking can be saved to thereby reduce patient burden and which enables safe drug-taking. [MEANS FOR SOLVING PROBLEMS] A liquid drug preparati...  
WO/2007/114791A1
The invention relates to a pharmaceutical composition containing 250 to 5000 millimoles per liter of lactate or lactic acid, 0.5 to 1.99 millimoles per liter of calcium and optionally 2 to 10 millimoles per liter of potassium. The invent...  
WO/2007/114461A1
Disclosed is a process for production of a composition having a carotenoid content of 80% or more, which comprises: extracting a culture of a microorganism, a condensation product of the culture or a dried product of the culture or the c...  
WO/2007/109893A1
The present invention relates to compositions and methods for reducing the cellular toxicity of a fume, particularly in relation to pulmonary inflammation, cytokine imbalance and lung disease. Plant extracts to be used with the compositi...  
WO/2007/109892A1
The present invention relates to compositions and methods for reducing the concentration of noxious substances in gases and smoke. Filters comprising plant extracts, such as parenchyma tissue extract and mesophyll cell extract, are also ...  
WO2007092458A8
The present application discloses the use of compounds exhibiting both acetylcholinesterase (AchE) inhibition properties and s-1 receptor agonist capacities for treating a mammal exposed to an exogenous neurotoxic agent, in particular ne...  
WO/2007/108438A1
A component capable of promoting glutathione production with enhanced effectiveness, and an external composition for use in promoting of glutathione production. Both γ-tocopherol and δ-tocopherol exhibit strikingly high glutathione pro...  
WO/2007/109804A2
The present invention relates to extracts of cinnamon species plant material prepared by supercritical CO2 extractions methods.  
WO/2007/105547A1
The invention provides methods for improving the absorbability and antioxidant ability of myricetin in the body. Either of the methods can be achieved by binding one or a plurality of glucosyl groups to the oxygen atom at the 3 or 3' pos...  
WO/2007/101365A1
The invention discloses a new flavane compound of formula (I) and its uses. The new flavane compound has antiinflammatory, antiallergic, antiviral and antioxidative effect, which is used to prepare antiinflammatory medicines or antialler...  
WO/2007/101349A1
A composition comprising Evodia rutaecarpia, green tea, black pepper and Cissus quandrangulans extracts, yohimbine and caffeine anhydrous for the purpose of reducing body fat mass and thus promoting weight loss The ingredients of the com...  
WO/2007/102735A1
The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there i...  
WO/2007/102572A1
A novel inhibitor for cellular aging which can effectively and fundamentally inhibit cellular aging. This inhibitor for cellular aging contains, as the active ingredient, a substance capable of inhibiting the expression of a gene encodin...  
WO/2007/101068A3
A method of treating and/or managing cystic fibrosis in a patient by administering an electrolyzed saline solution containing hypohalous acid. Preferably, the hypohalous acid is hypochlorous acid. Also provided is a method of treating an...  
WO/2007/099828A1
Nitrogenous heterocyclic derivatives represented by the general formula (I) which each bind specifically to NR1/NR2B receptor and are useful as NR2B receptor antagonists (particularly analgesic for cancer pain or neuroprotectant); pharma...  

Matches 601 - 650 out of 9,396